Search

Author/Creator Liu, S V

2. 49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). (17th December 2018)

Authors:
Califano, R; Każarnowicz, A; Karaseva, N; Sánchez, A; Liu, S V; Horn, L; Quach, C; Yu, W; Kabbinavar, F; Lam, S; Mansfield, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 63ONRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib. (24th November 2019)

Authors:
Goto, Y; Cadranel, J; Weinberg, B A; Duruisseaux, M; Liu, S V; Tolba, K; Branden, E; Doebele, R C; Heining, C; Schlenk, R F; Laskin, J J; Cheema, P K; Jones, M R; Trombetta, D; Muscarella, L A; Cseh, A; Solca, F; Renouf, D J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (25th November 2018)

Authors:
Mok, T S K; Reck, M; Horn, L; Lam, S; Shames, D S; Liu, J; Kabbinavar, F; Lin, W; Sandler, A; Liu, S V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. (25th November 2018)

Authors:
Demetri, G D; Paz-Ares, L; Farago, A F; Liu, S V; Chawla, S P; Tosi, D; Kim, E S; Blakely, C M; Krauss, J C; Sigal, D; Bazhenova, L; John, T; Besse, B; Wolf, J; Seto, T; Chow-Maneval, E; Multani, P S; Johnson, A; Simmons, B; Doebele, R C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (3rd September 2019)

Authors:
Mountzios, G; Remon, J; Novello, S; Blais, N; Califano, R; Cufer, T; Dingemans, A M; Liu, S V; Peled, N; Pennell, N A; Reck, M; Rolfo, C; Tan, D; Vansteenkiste, J; West, H; Besse, B
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1686
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗